Hyun C Chung, ASCO GI 2021: Lenvatinib plus Pembrolizumab in Patients with Advanced Solid Tumours
We were delighted to talk to Hyun C Chung (Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea) about the combination of lenvatinib plus pembrolizumab in the treatment of patients with advanced solid tumours (Clinical Trial Identifier: NCT03797326).
The abstract ‘LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort.’ (ABSTRACT NUMBER: 230) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- What is the rationale for the use of lenvatinib plus pembrolizumab in patients with advanced solid tumours? (0:05)
- Which patients are most likely to respond to this combination? (1:06)
Disclosures: Hyun C Chung discloses Grant/Research Support from Lilly, GSK, MSD, Merck-Serono, BMS/Ono, Taiho, Amgen, Beigene, Incyte and Zymework; Honoraria from Merck-Serono and Lilly; Consultation for Taiho, Celltrion, MSD, Lilly, BMS, Merck-Serono, Gloria, Beigene, Amgen and Zymework.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Immuno-oncology
Tumour-selective targeted delivery of antibody-cytokine fusion proteins: Jamie Spangler, AACR 2023
Antibody-cytokine fusion proteins are a promising immunotherapy that could overcome off-target immune cell activation and the short serum half-life associated with low-dose interleukin-2 treatment. We were delighted to talk with Dr. Jamie Spangler (Johns Hopkins University, Baltimore, MD, USA) around the rationale for fusing cytokines to anti-cytokine antibodies in targeted therapy, the improved therapeutic efficacy […]
DNA damage as a target and predictor of treatment response in immunotherapy: Sandra Demaria, AACR 2023 (Part 2)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. It was a pleasure to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) to discuss how radiation-induced DNA damage is targeted in treatment strategies with immunotherapy, […]
Radiation-induced DNA damage response and tumour immunogenicity: Sandra Demaria, AACR 2023 (Part 1)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. We were delighted to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) around the radiation-induced DNA damage response, its association with cancer and how this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!